In English | En español
Questions About Cancer? 1-800-4-CANCER

Liver (Hepatocellular) Cancer Screening (PDQ®)

  • Last Modified: 01/25/2012

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document

Summary of Evidence

Benefits
Harms

Note: Separate PDQ summaries on Adult Primary Liver Cancer Treatment and Childhood Liver Cancer Treatment are also available.

Benefits

Based on fair evidence, screening would not result in a decrease in mortality from hepatocellular cancer.

Magnitude of Effect: No reduction in mortality.

Study Design: Randomized controlled trials.
Internal Validity: Fair.
Consistency: Multiple studies, large number of participants.
External Validity: Fair.
Harms

Based on fair evidence, screening would result in rare but serious side effects associated with needle aspiration cytology such as needle-track seeding, particularly of lesions more than 2 cm in diameter, and hemorrhage, bile peritonitis, and pneumothorax. Transjugular liver biopsy is rarely associated with major complications such as perforation of the hepatic capsule or cholangitis.

Magnitude of Effect: Good evidence for uncommon but serious harms.

Study Design: Randomized controlled trials and observational studies.
Internal Validity: Fair.
Consistency: Multiple studies, large number of participants.
External Validity: Good.